- Home
- CIFR vs CLDX Comparison
CIFR vs CLDX Comparison
Compare CIFR & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- CLDX
- Stock Information
- Founded
- CIFR 2021
- CLDX N/A
- Country
- CIFR United States
- CLDX United States
- Employees
- CIFR N/A
- CLDX N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CIFR Finance
- CLDX Health Care
- Exchange
- CIFR Nasdaq
- CLDX Nasdaq
- Market Cap
- CIFR 1.2B
- CLDX 1.3B
- IPO Year
- CIFR N/A
- CLDX 2008
- Fundamental
- Price
- CIFR $3.79
- CLDX $20.50
- Analyst Decision
- CIFR Strong Buy
- CLDX Buy
- Analyst Count
- CIFR 10
- CLDX 9
- Target Price
- CIFR $7.58
- CLDX $50.00
- AVG Volume (30 Days)
- CIFR 23.3M
- CLDX 1.2M
- Earning Date
- CIFR 08-12-2025
- CLDX 08-07-2025
- Dividend Yield
- CIFR N/A
- CLDX N/A
- EPS Growth
- CIFR N/A
- CLDX N/A
- EPS
- CIFR N/A
- CLDX N/A
- Revenue
- CIFR $152,092,000.00
- CLDX $7,559,000.00
- Revenue This Year
- CIFR $88.07
- CLDX N/A
- Revenue Next Year
- CIFR $68.21
- CLDX N/A
- P/E Ratio
- CIFR N/A
- CLDX N/A
- Revenue Growth
- CIFR N/A
- CLDX 24.49
- 52 Week Low
- CIFR $1.86
- CLDX $14.40
- 52 Week High
- CIFR $7.99
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- CIFR 54.27
- CLDX 52.11
- Support Level
- CIFR $3.63
- CLDX $19.77
- Resistance Level
- CIFR $3.98
- CLDX $24.03
- Average True Range (ATR)
- CIFR 0.30
- CLDX 1.31
- MACD
- CIFR -0.02
- CLDX -0.00
- Stochastic Oscillator
- CIFR 62.28
- CLDX 26.15
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.